Management of intramedullary spinal cord tumors

Das, KuntalKanti; Pattankar, Sanjeev; Sardhara, Jayesh; Jaiswal, AwadheshKumar

doi:10.4103/joss.joss_21_22

Cited by 2 publications

(2 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intradural extramedullary spinal cord tumors (EMSCTs) develop in the subdural space, outside of the spinal cord, and are the second most common spinal tumor, constituting 40% [6]. They typically arise from leptomeninges or nerve roots [8]. Among EMSCTs, Schwannomas are the most prevalent, accounting for 29%, followed by meningiomas at 25%, and gliomas at 22% [9].…”

Section: Introductionmentioning

confidence: 99%

States of Arts and New Approaches to Spinal Cord Tumors

Kumawat,

Takahashi,

Date

et al. 2024

Preprint

View full text Add to dashboard Cite

Spinal cord tumors, though rare, present formidable challenges in clinical management due to their intricate nature. Traditional treatment modalities like surgery, radiation therapy, and chemotherapy have been the mainstay for managing these tumors. However, despite significant advancements, challenges persist, including the limitations of surgical resection and the potential side effects associated with radiation therapy. In response to these limitations, a wave of innovative approaches is reshaping the treatment landscape for spinal cord tumors. Advancements in gene therapy, immunotherapy, and targeted therapy are offering groundbreaking possibilities. Gene therapy holds the potential to modify the genes responsible for tumor growth, while immunotherapy harnesses the body's own immune system to fight cancer cells. Targeted therapy aims to strike a specific vulnerability within the tumor cells, offering a more precise and potentially less toxic approach. Additionally, novel surgical adjuncts are being explored to improve visualization and minimize damage to surrounding healthy tissue during tumor removal. These developments pave the way for a future of personalized medicine for spinal cord tumors. By delving deeper into the molecular makeup of individual tumors, doctors can tailor treatment strategies to target specific mutations and vulnerabilities. This personalized approach offers the potential for more effective interventions with fewer side effects, ultimately leading to improved patient outcomes and a better quality of life. This evolving landscape of spinal cord tumor management signifies the crucial integration of established and innovative strategies to create a brighter future for patients battling this complex condition.

show abstract

Section: Introductionmentioning

confidence: 99%

States of Arts and New Approaches to Spinal Cord Tumors

Kumawat,

Takahashi,

Date

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…It originates in the spinal cord itself, causing its invasion and destruction of white and gray matter. 1 However, a spinal cord lesion can also be linked to a lymphoma. Primary intramedullary spinal cord lymphoma (PISCL) is one of the rarest spinal diseases, comprising 1% of all CNS lymphomas.…”

Section: Introductionmentioning

confidence: 99%

B-Cell Lymphoma Intramedullary Tumor: Case Report and Systematic Review

Gonsalves¹,

Raffa²,

Sousa

et al. 2023

Asian J Neurosurg

View full text Add to dashboard Cite

Intramedullary tumors represent the major cause of spinal cord injuries, and its symptoms include pain and weakness. Progressive weakness may concomitantly occur in the upper and lower limbs, along with lack of balance, spine tenderness, sensory loss, trophic changes of extremity, hyperreflexia, and clonus. The study protocol was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A systematic search of the MEDLINE electronic database was performed to identify the studies reporting the clinical features of children and adults who presented with an intramedullary lymphoma. Twenty-one studies were included, reporting 25 cases. Manuscripts were excluded if the full-text article was not available, original data were not reported (e.g., review articles), or if the main disease was not intramedullary lymphoma. A structured data extraction form was employed to standardize the identification and retrieval of data from manuscripts. To enlighten the discussion, a case is also presented. An 82-year-old woman with Fitzpatrick skin type II, diagnosed and treated for non-Hodgkin's lymphoma 7 years ago, was admitted with mental confusion and memory loss for the past 2 months—evolving with recurring falls from her own height. One day before admission, she displayed Brown-Séquard syndrome. An expansive lesion from C2 to C4 in the cervical spinal cord was found and a hypersignal spinal cord adjacent was described at the bulb medullary transition to the C6–C7 level. A primary spinal cord tumor was considered, as well as a melanoma metastasis, due to the lesion's flame pattern. The patient presented a partial recovery of symptoms and a reduction of the spinal cord edema after being empirically treated with corticosteroids, but the lesion maintained its extent. Subsequently, a large diffuse B-cell lymphoma with nongerminal center was found in open body biopsy, infiltrating neural tissue. The main objective of the present study is to report a surgical case treated for a large diffuse B-cell lymphoma, in addition to presenting the results of a systematic review of primary intramedullary spinal cord lymphoma.

show abstract

Management of intramedullary spinal cord tumors

Cited by 2 publications

References 66 publications

States of Arts and New Approaches to Spinal Cord Tumors

States of Arts and New Approaches to Spinal Cord Tumors

B-Cell Lymphoma Intramedullary Tumor: Case Report and Systematic Review

Contact Info

Product

Resources

About